
PCCM attending @MMC, former PCCM fellow @UMMC, Chief Medical Resident @weillcornell,Graduate of WCMC-Q@18, NYP/WC@21, Tweets are my own.#MedEd#ILD#physiology
Joined January 2011
- Tweets2.2K
- Following642
- Followers253
- Likes2K
Youmna Abdelghany retweeted
#ReviewCourse ACR: Drugs & Pregnancy ➡️ Avoid MTX, leflunomide and mycophenolate. HCQ, sulfasalazine, colchicine and AZA: compatible in pregnancy/lactation.
👁️ AZA Compatible with pregnancy, but linked to cholestasis. Check bile acids if itching; stop if confirmed. #ACR26
Youmna Abdelghany retweeted
🔥Hot off the press for #ACR26 🔥
The @IgG4ward foundation guidelines on the treatment of IgG4-related disease
thelancet.com/journals/lanrh…
Free to read on lancet.com
Youmna Abdelghany retweeted
🧵 IgG4-related disease: New treatment guidelines for 2026
The IgG4ward! Foundation guidelines, published in The Lancet Rheumatology (November 9, 2026), provide a major update to the 2015 treatment framework.
Here are 10 key updates for clinicians.
#RheumattDoc #MedTwitter #RheumTwitter #rheumatology #igg4relateddisease @docakx @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1
Youmna Abdelghany retweeted
ERR: Haemoptysis is a rare but potentially life-threatening complication of chronic pulmonary vascular diseases. This review summarises the current knowledge of its pathophysiology and provides guidance on contemporary diagnostic and treatment strategies. bit.ly/4bEObtV
Youmna Abdelghany retweeted
FVC declines by 20–30 mL per year after early adulthood. Women show a linear fall, men a biphasic decline. Clinicians should contextualise trajectories in terms of age and sex. Declines above normal range may signal underlying disease/treatment failure. bit.ly/4aM8Vzv
Youmna Abdelghany retweeted
New content online: Navigating evidence-based recommendations for the management of systemic sclerosis dlvr.it/TTrnzy
Youmna Abdelghany retweeted
“Tofacitinib is NOT Toffee-citinib.” 🍬
You can’t just unwrap it and hand it over.
Every week, patients are started on JAK inhibitors without baseline screening. That’s a preventable mistake.
Before the first tablet, ask yourself:
🔍 TB screened?
🦠 Hepatitis B (HBsAg + anti-HBc + anti-HBs)?
🩸 HIV/HCV checked?
🧪 CBC, LFT, RFT & Lipids done?
❤️ MACE & VTE risk assessed?
🎗️ Age-appropriate malignancy screening completed?
💉 Vaccinations updated (Influenza, Pneumococcal, COVID-19, Hepatitis B, RZV, HPV where indicated)?
JAK inhibitors are powerful—not casual prescriptions.
Don’t prescribe first and investigate later.
Screen. Vaccinate. Then JAK.
Because Tofacitinib isn’t Toffee… and complications aren’t sweet either. 🍬❌
#JAKInhibitors #Tofacitinib #Rheumatology #ClinicalImmunology #PatientSafety #MedTwitter #EvidenceBasedMedicine #TreatSmart – at Lucknow, India
🤖 Made with AI
Youmna Abdelghany retweeted
Rarely, chronic eosinophilic pneumonia progresses to fibrosis. Anti-IL-5/IL-5R treatment is effective as a steroid-sparing agent and has a rationale in reducing the risk of fibrosis. Antifibrotic treatment is available in progressive fibrosis patients. bit.ly/4nc8CCK
Youmna Abdelghany retweeted
NEW | APLAR 2026 Reproductive Consensus in AIRDs
Pre-conception
✅ Plan pregnancy after ≥6 months remission/LDA
✅ Continue: HCQ, AZA, SSZ, CSA, TAC, Colchicine, TNFi
❌ Stop: MTX (1–3 mo), MMF (6 wks), CYC (3 mo), JAKi (2 wks), LEF (washout or ≥3.5 mo)
Pregnancy
✅ HCQ throughout
✅ LDA for all SLE
✅ Prednisolone (lowest dose; ideally ≤5 mg/day)
✅ TNFi throughout pregnancy
✅ AZA, TAC, CSA, SSZ safe
⚠️ MTX/MMF contraindicated; CYC only 2nd/3rd trimester for life-threatening disease
⚠️ NSAIDs only ≤28 weeks
APS
• Obstetric APS → LDA + prophylactic LMWH till 6–12 wks postpartum
• Thrombotic APS → LDA + therapeutic LMWH
Anti-Ro/SSA/La
• Fetal cardiac surveillance 16–26 weeks
• Weekly if prior CHB
Lactation
✅ HCQ, AZA, SSZ, CSA, TAC, TNFi compatible
❌ Avoid: MTX, MMF, LEF, CYC, JAKi
Infants exposed to TNFi (except certolizumab): Delay BCG to 6 months.
Lead Author: Dr. Vinod Ravindran
DOI: 10.1111/1756-185X.70751
#APLAR #Rheumatology #Pregnancy #SLE #APS #Lupus #MedTwitter #EvidenceBasedMedicine
🤖 Made with AI
Youmna Abdelghany retweeted
🚨 NEJM Review 2026 | Inflammatory Myopathies
📌 5 major IIM subsets:
▪️ IBM
▪️ IMNM
▪️ ASyS
▪️ Dermatomyositis
▪️ Overlap myositis
📊 Epidemiology
• Incidence: 0.79/100,000 PY
• Prevalence: 14/100,000
• ~70% have myositis-specific autoantibodies
🧬 Autoantibody pearls
🔹 Anti-MDA5 → RP-ILD in ~30% | Mortality >50%
🔹 Anti-TIF1γ / NXP2 → highest cancer risk
🔹 Anti-PL7 / PL12 > worse ILD survival
🔹 Anti-SRP → severe weakness
🔹 Anti-HMGCR → statin-associated IMNM
🫁 Organ involvement
• ILD in >80% ASyS / MDA5+ DM
• Cancer in ~10% adults within ±3 yrs
• Dysphagia = major severity marker
• Cardiac involvement ~5%
• Joint involvement ~20%
📌 CK patterns
▪️ IBM → 2–4× ULN
▪️ DM → 1–10× ULN (can be normal!)
▪️ ASyS → 10–20× ULN
▪️ IMNM → 20–30× ULN
🧠 Key clinical clues
• IBM → asymmetric quadriceps + finger flexors
• ⅓ ASyS may NOT develop myositis
• ≥⅓ DM can be amyopathic
💥 Therapeutic era shift
✅ IVIG approved in DM
✅ Rituximab effective in ASyS-ILD
✅ JAK/TYK2 inhibitors promising
✅ FcRn blockade + CAR-T = next frontier
❌ IBM remains treatment-resistant
🏃 Exercise 3×/week improves strength & QoL
📖 NEJM 2026
DOI: 10.1056/NEJMra2415426
#Myositis #Dermatomyositis #IMNM #AntisynthetaseSyndrome #Rheumatology #ILD #Autoantibodies #NEJM #MedTwitter #Rheumtwitter
Youmna Abdelghany retweeted
Lecture: 2025 Updates on ILD Classification.
A lecture I gave last week for the ICRI Chest series.
youtu.be/guVSRvIVY-k
#ctchest #ctchestreview #ILD #ILDguidelines
Youmna Abdelghany retweeted
🧠 Cancer screening in idiopathic inflammatory myopathies (IIM)
🧭 Step 1: Identify IIM type
•Juvenile IIM / IBM → No routine cancer screening required
•Adult-onset IIM → proceed to risk stratification
⚖️ Step 2: Risk stratification
🔴 High-risk factors
Subtype
•Dermatomyositis
Antibodies
•Anti–TIF1-γ
•Anti–NXP2
Clinical
•Age > 40 at onset
•Persistent high disease activity
•Moderate–severe dysphagia
•Cutaneous necrosis
🟡 Intermediate-risk factors
Subtype
•CADM
•Polymyositis
•IMNM
Antibodies
•Anti-SAE1
•Anti-HMGCR
•Anti-Mi2
•Anti-MDA5
Clinical
•Male sex
🟢 Low-risk factors
Subtype
•ASSD
•CTD-associated myositis
Antibodies
•Anti-SRP
•Anti-Jo1
•Non-Jo1 ASSD antibodies
•MAA
Clinical
•Raynaud’s
•Inflammatory arthritis
•ILD
🧮 Step 3: Assign overall cancer risk
🔴 High risk
•≥2 high-risk factors
👉 Screening
•At diagnosis: Basic + Enhanced panel
•Follow-up: Basic screening at 1, 2, 3 years
•Consider:
•FDG PET-CT
•Upper & lower GI endoscopy
🟡 Moderate risk
•≥2 intermediate OR 1 high-risk factor
👉 Screening
•At diagnosis: Basic + Enhanced
•Follow-up: No routine repeat
🟢 Standard risk
•Does not meet above criteria
👉 Screening
•At diagnosis: Basic only
•Follow-up: None
🧪 What’s included in screening?
Basic panel
•History + exam
•CBC
•LFT
•ESR/CRP
•SPEP
•Urinalysis
•Chest X-ray
Enhanced panel
•CT neck/thorax/abdomen/pelvis
•Cervical screening
•Mammography
•PSA
•CA-125
•Pelvic USG
•FOBT
🌏 Special note
•Consider nasoendoscopy in regions with high nasopharyngeal carcinoma risk
🔑 Take home
•Dermatomyositis + TIF1-γ/NXP2 + older age = highest cancer risk
•Screening intensity is front-loaded at diagnosis, with follow-up mainly for high-risk patients
#RheumattDoc #MedTwitter #RheumTwitter #Medicine #rheumatology @DrAkhilX @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1
Youmna Abdelghany retweeted
🧵 Why can oxygen worsen respiratory failure in COPD?
Many clinicians still fear giving oxygen to COPD patients.
The reason they’re taught?
"Loss of hypoxic drive"
But this is mostly a myth.
Here’s what really causes oxygen-induced hypercapnia 👇
Youmna Abdelghany retweeted
New Pulm PEEPs pearls ⭐️ episode out today about non-pharmacologic airway clearance for patients with non-CF bronchiectasis!
From breathing techniques to percussion, listen in for some key points and takeaways.
pulmpeeps.com/2026/01/06/114…
Image source: link.springer.com/article/10…
Youmna Abdelghany retweeted
Breathe: Novel therapies, like ensifentrine and dupilumab, represent a shift towards personalised COPD management by targeting specific inflammatory pathways and improving outcomes in patients with eosinophilic endotypes. bit.ly/4qmnBLG
Youmna Abdelghany retweeted
Radiologic comment on the case:
The HRCT features of hypersensitivity pneumonitis (HP) in this case include centrilobular ground-glass nodules, ground-glass opacities (diffuse or patchy), lobular mosaic attenuation on inspiratory images with corresponding air trapping on expiratory images, and the three-density sign (combined ground-glass opacities and mosaic attenuation).
Before discussing which of these features are typical or compatible with HP, two important points should be clarified.
First, according to the updated International Multidisciplinary Classification of the Interstitial Pneumonias, bronchiolocentric interstitial pneumonia (BIP) has been introduced as a distinct morphologic pattern. This pattern essentially describes the constellation of imaging findings traditionally associated with HP. Importantly, these features are not specific to HP and may also be encountered in other clinical contexts, including connective tissue disease–associated ILD (1).
Second, there are currently two major HP classification systems: the ATS/JRS/ALAT 2020 clinical practice guideline (2) and the ACCP (CHEST) 2021 guideline (3). Both classify HP into fibrotic and nonfibrotic types. However, although both further categorize HRCT patterns into typical, compatible, and indeterminate, the definitions and practical application of these subtypes differ substantially.
From a radiologist’s perspective, I lean toward the ACCP classification, which I find more practical and applicable to daily HRCT interpretation, particularly after the formal introduction of BIP as an interstitial pneumonia pattern. This preference is supported by a Radiology: Cardiothoracic Imaging study comparing the diagnostic performance of both systems, which demonstrated that the ATS/JRS/ALAT classification is more specific in low-prevalence HP settings, whereas the ACCP classification is more sensitive in high-prevalence HP populations (4).
Based on this, in my opinion, after the introduction of BIP, it is more appropriate in low-prevalence HP settings to report a BIP pattern radiologically rather than forcing HP sub-classification in the absence of a relevant antigen exposure. In contrast, in high-prevalence settings, or when there is a clear exposure history (as in this case), applying HP classification becomes logical. In such scenarios, the ACCP system—being more sensitive—appears better suited, allowing us to diagnose a BIP pattern most consistent with HP and then proceed with ACCP-based HP subtyping.
According to the ACCP framework, typical HP features include the three-density sign, profuse centrilobular nodules and the combination of nonprofuse centrilobular nodules with mosaic attenuation, whereas isolated nonprofuse centrilobular nodules, ground-glass opacities, or mosaic attenuation alone are considered compatible features. In this case, although the centrilobular nodules are nonprofuse, their coexistence with mosaic attenuation, together with the presence of the three-density sign, fulfills two ACCP-defined typical features.
Conclusion:
The HRCT demonstrates a BIP pattern with no imaging evidence of fibrosis, and in the context of a strong history of bird exposure, the findings are most consistent radiologically with nonfibrotic, Typical hypersensitivity pneumonitis.
⸻
References:
1.Ryerson CJ et al. Update of the International Multidisciplinary Classification of the Interstitial Pneumonias. Eur Respir J. 2025 (in press). doi:10.1183/13993003.00158-2025
2.Raghu G et al. Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020. doi:10.1164/rccm.202005-2032ST
3. Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report. CHEST. 2021
4.Chelala L et al. Hypersensitivity Pneumonitis on Thin-Section CT: ATS/JRS/ALAT vs ACCP Performance. Radiology: Cardiothoracic Imaging. 2024;6(4):e230068
📌 Case Discussion
47-year-old female with significant bird exposure.
Her HRCT is shared below.
The scan demonstrates all the characteristic features of hypersensitivity pneumonitis (HP).
⸻
🔍 Questions to colleagues:
1️⃣ When we interpret HP on HRCT, what is the very first step?
👉 The first step — is to decide whether the pattern is:
•Fibrotic HP, or
•Nonfibrotic HP.
This is always the starting point.
⸻
2️⃣ This case shows all the HRCT features of HP.
What are these features — all of them — that make you think of HP?
⸻
3️⃣ A key principle in HP subtype classification:
👉 If there is one typical feature, the pattern is classified as Typical HP, even if other findings are only compatible.
So:
•Which of the features in this case are “Typical HP”?
•Which features are “Compatible with HP”?
Youmna Abdelghany retweeted
🔗 Overlap Syndromes
Overlap syndrome = coexistence of features of ≥2 systemic autoimmune rheumatic diseases in the same patient 🧩
All MCTD are overlap syndromes, but not all overlap syndromes are MCTD ✅
🧬🤝 Common Overlap Patterns
🧊 SSc + PM/DM
➡️ 💪 Myositis | 🌬️ ILD | 🖐️ Raynaud | 🧱 Skin thickening
🌙🧊 SLE + SSc
➡️ 🖐️ Raynaud | 🌬️ ILD | 🧪 Anti-U1 RNP
🦴🌙 RA + SLE (Rhupus)
➡️ 🦴 Erosive arthritis | 🧬 Lupus features
🧩 MCTD
➡️ 🌙 SLE + 🧊 SSc + 💪 PM
➡️ 🧪🔥 High-titer Anti-U1 RNP
🧪🔍 Autoantibodies – Diagnostic Clues
🧪 Anti-U1 RNP → 🧩 MCTD | 🌙🧊 SLE–SSc
🧪 Anti-PM/Scl → 🧊💪 SSc–Myositis
🧪 Anti-Ku → 🧊💪🌙 SSc–Myositis–SLE
🧪 Anti-Ro52 → 💪🌬️ Myositis-ILD | 💧 Sjögren’s
🧪 Anti-CCP + ANA → 🦴🌙 Rhupus
🫁❤️ Major Organ Involvement (⚠️ Often Severe)
🌬️ Interstitial lung disease
❤️ Pulmonary arterial hypertension
💪 Inflammatory myopathy
🩺 Renal disease (SLE-dominant)
📌⚖️ Key Points
❌ Overlap ≠ MCTD
✔️ MCTD → 🧪🔥 High-titer anti-U1 RNP + criteria
⏳ Disease phenotype may evolve over time
🎯 Prognosis driven by lung & pulmonary disease
🩺💊 Management Principles
🎯 Treat dominant organ involvement
💊 Steroids
🧬 MTX | MMF | AZA | CYC
🎯 Biologics (e.g., Rituximab)
👥 Multidisciplinary care
🧠✨ Take-home
When one CTD isn’t enough - think overlap!
🧪 Antibodies guide diagnosis
🫁 Organs guide treatment
#RheumattDoc #MedTwitter #RheumTwitter #rheumatology @DrAkhilX @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1 @Urchilla01
🧩🧬 Anti-RNP: A Piece of the Puzzle
🚨🧬 Honest question: how often is MCTD labeled just because RNP is positive?
🎯 Anti-U1 RNP is necessary but not sufficient for MCTD (Mixed Connective Tissue Disease)
⬇️ Here are the classification criteria
🧬✨ MCTD Classification Criteria
1️⃣ Alarcón-Segovia Criteria
🧪 Serology (Mandatory)
•🔬 Anti-U1 RNP ≥ 1:1600
🏥 Clinical (≥ 3 required)
•🤲 Swollen hands
•🦴 Synovitis
•💪 Myositis
•✋ Sclerodactyly
•❄️ Raynaud’s phenomenon
📊 Diagnostic Performance
•🎯 Sensitivity: ~ 60–70%
•🛡️ Specificity: ~ 90–95%
2️⃣ Kahn Criteria
🧪 Serology (Mandatory)
•🔬 Anti-U1 RNP ≥ 1:1200
🏥 Clinical
•❄️ Raynaud’s phenomenon
➕ ≥ 2 of:
•🤲 Swollen fingers
•🦴 Synovitis
•💪 Myositis
📊 Diagnostic Performance
•🎯 Sensitivity: ~ 70–75%
•🛡️ Specificity: ~ 85–90%
3️⃣ Kasukawa Criteria
🧪 Serology (Mandatory)
•🔬 Anti-U1 RNP positive
🏥 Clinical Requirement
•✅ ≥ 1 Common feature
•➕ ≥ 1 feature from ≥ 2 overlap diseases
🔹 Common Findings
•❄️ Raynaud’s phenomenon
•🤲 Swollen fingers / hands
🟣 SLE-like Features
•🦴 Polyarthritis
•🧠 Lymphadenopathy
•😊 Facial erythema
•🫀 Pericarditis / 🫁 Pleuritis
•🧪 Leukopenia / Thrombocytopenia
🔵 Systemic Sclerosis-like
•✋ Sclerodactyly
•🫁 Pulmonary fibrosis / ↓ DLCO / restrictive PFT
•🍽️ Esophageal hypomotility / dilatation
🟠 Polymyositis-like
•💪 Muscle weakness
•📈 Elevated CK
•⚡ Myogenic EMG
📊 Diagnostic Performance
•🎯 Sensitivity: ~ 80–90% ⭐ (highest)
•🛡️ Specificity: ~ 70–80%
🧠 Take home
•🛡️ Most specific → Alarcón-Segovia
•🎯 Most sensitive → Kasukawa
#RheumattDoc #MedTwitter #RheumTwitter #rheumatology @DrAkhilX @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1
Youmna Abdelghany retweeted
European Respiratory Journal: This update builds upon the previous classification approach by describing major advances in the classification of interstitial pneumonia over the past decade bit.ly/41oWvZl
Youmna Abdelghany retweeted
Myositis in SLE is often missed.
Look for MRI edema, Ro52 positivity, necrotizing features, and interferon-driven pathways.
Early steroids + MMF/Rituximab change outcomes.
@DrAkhilX @IhabFathiSulima @abledoc @Myositis_India @docrota #MedTwitter #RheumTwitter #Myositis #SLE #Lupus
🧩 Understanding the Myositis Profile
A key tool in diagnosing idiopathic inflammatory myopathies (IIM).
It identifies:
✅ Myositis-specific antibodies (MSA) – unique to myositis
✅ Myositis-associated antibodies (MAA) – seen in overlap syndromes
#Rheumatology #Myositis #Autoantibodies #MedTwitter @DrAkhilX @IhabFathiSulima @CelestinoGutirr
Youmna Abdelghany retweeted
🔥 The ACR–EULAR RA Treatment Guidelines (2023–24) — in 12 ultra-simple visuals.
If you treat RA, THIS is your entire roadmap. Save it. Share it. Teach with it.
MTX → Treat-to-Target → Early biologics/JAKi → Minimal steroids → Comorbidity-based choices → Safe tapering.
These 12 slides make RA management easier than ever.
👇🧵 Full infographic set below
#Rheumatology #ACR #EULAR #MedTwitter #RA #MedicalEducation #Immunology #DMARDs #Biologics #JAKinhibitors #Rheum @DrAkhilX @IhabFathiSulima @DrNikhilMD @ACRheum @eular_org
🧵 Drugs Used in Rheumatoid Arthritis: An Updated Overview
RA is no longer a “wait and watch” disease. Early, aggressive therapy has changed outcomes.
Let’s break down the drug arsenal used to fight this chronic autoimmune enemy.
#Rheumatology #MedTwitter @IhabFathiSulima @DrAkhilX @ACRheum







































